Calidi Biotherapeutics, Inc. Granted New Patent from USPTO for Cell-Based Delivery Of Oncolytic Vaccinia Viruses
SAN DIEGO, October 25, 2018 – Calidi Biotherapeutics, Inc., a clinical‐stage biotherapeutics company at the forefront of oncolytic virus-based immunotherapies for cancer, today announced that it has been granted a…